FDA to evaluate risk of cardiovascular events with sibutramine
The FDA has notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine (Meridia, from Abbott) have a higher number of cardiovascular events than patients receiving placebo.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.